Entos Pharmaceuticals Inc. has been awarded a $4 million grant by California Institute for Regenerative Medicine (CIRM) to support the completion of IND-enabling activities with ENTLEP-001, a durable genetic medicine for the treatment of congenital generalized lipodystrophy.
Biopharma nonprofit deals remained low in 2024, compared to the pandemic and pre-pandemic years, while grants saw a slight decline from the previous year.
Ymmunobio AG, in collaboration with the Paul Scherrer Institute, has received an Innosuisse grant to develop innovative radioactive loaded antibodies for the treatment and diagnosis of solid tumors based on Ymmunobio’s proprietary YB-800.